Heska Corporation (HSKA) Given Average Rating of “Hold” by Analysts
Shares of Heska Corporation (NASDAQ:HSKA) have earned a consensus rating of “Hold” from the eight research firms that are currently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $106.40.
HSKA has been the topic of several research reports. Canaccord Genuity initiated coverage on Heska Corporation in a report on Thursday, October 5th. They issued a “buy” rating and a $115.00 target price on the stock. Benchmark Co. lifted their target price on Heska Corporation from $106.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. BidaskClub raised Heska Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 3rd. Aegis lifted their target price on Heska Corporation from $114.50 to $129.50 and gave the stock a “buy” rating in a report on Tuesday, August 1st. Finally, Zacks Investment Research cut Heska Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th.
Heska Corporation (NASDAQ:HSKA) traded up 0.11% during trading on Thursday, hitting $97.12. The stock had a trading volume of 32,455 shares. The company has a 50-day moving average of $94.57 and a 200 day moving average of $98.34. Heska Corporation has a 52-week low of $46.51 and a 52-week high of $115.00. The firm has a market cap of $701.79 million, a P/E ratio of 49.50 and a beta of 0.84.
Heska Corporation (NASDAQ:HSKA) last issued its earnings results on Thursday, August 3rd. The medical research company reported $0.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.07. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The firm had revenue of $34.30 million for the quarter, compared to analysts’ expectations of $33.35 million. During the same period in the previous year, the firm posted $0.35 earnings per share. The business’s revenue was up 14.3% compared to the same quarter last year. On average, equities research analysts predict that Heska Corporation will post $2.04 earnings per share for the current fiscal year.
In related news, EVP Nancy Wisnewski sold 825 shares of Heska Corporation stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $102.21, for a total value of $84,323.25. Following the completion of the transaction, the executive vice president now owns 38,114 shares in the company, valued at $3,895,631.94. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO John Mcmahon sold 2,608 shares of Heska Corporation stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total value of $263,851.36. Following the completion of the transaction, the chief financial officer now owns 193 shares of the company’s stock, valued at approximately $19,525.81. The disclosure for this sale can be found here. Company insiders own 14.70% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HSKA. Victory Capital Management Inc. purchased a new position in Heska Corporation in the first quarter worth about $101,000. Royal Bank of Canada grew its position in Heska Corporation by 96.9% in the second quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after acquiring an additional 499 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in Heska Corporation by 1,306.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,167 shares of the medical research company’s stock worth $123,000 after acquiring an additional 1,084 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in Heska Corporation in the second quarter worth about $127,000. Finally, LS Investment Advisors LLC grew its position in Heska Corporation by 411.2% in the second quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock worth $130,000 after acquiring an additional 1,028 shares in the last quarter. Institutional investors own 81.36% of the company’s stock.
About Heska Corporation
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.